OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research report issued on Thursday. The brokerage set a “sell” rating on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and set a $4.25 price objective on shares of OncoCyte in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $4.06.

OncoCyte Trading Up 2.0 %

OncoCyte stock opened at $3.05 on Thursday. The stock has a 50-day moving average of $3.09 and a two-hundred day moving average of $2.93. OncoCyte has a one year low of $2.08 and a one year high of $4.34.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. The company had revenue of $0.10 million during the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.